SCHEDULE: State Street Discloses Akebia Therapeutics Stake

State Street Corporation has reported beneficial ownership of 4.3% of Akebia Therapeutics Inc. common stock as of March 31, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating its beneficial ownership of Akebia Therapeutics Inc. common stock.
• As of March 31, 2026, State Street Corporation beneficially owns 11,614,006 shares, representing 4.3% of the class of securities.
• The filing specifies that State Street Corporation has shared voting power over 11,269,922 shares and shared dispositive power over 11,614,006 shares.
• The reporting entity is State Street Corporation, a financial institution organized in Massachusetts.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it's a routine disclosure of institutional ownership without new strategic information or financial performance data.

Positives

• State Street Corporation's filing indicates a significant institutional investor holding a notable stake in Akebia Therapeutics.
• The filing confirms that the shares are held in the ordinary course of business, suggesting a standard investment approach rather than a hostile takeover attempt.

Risks

• While not explicitly stated as a risk, a significant stake by an institutional investor could lead to future activism or influence on corporate decisions.
• The filing does not provide details on the specific investment strategy or rationale behind holding this stake, which could be a point of inquiry for other investors.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Akebia Therapeutics Inc. It is a disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors crossing certain ownership thresholds. State Street Corporation, through its subsidiaries like SSGA Funds Management, Inc., is a major global asset manager, and its holdings in biotechnology companies like Akebia Therapeutics are typical within diversified portfolios.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's presence, which can be viewed positively as a sign of confidence, but it does not provide immediate actionable information for trading decisions.
• Management: The filing serves as a notification of ownership, which management will be aware of through regulatory filings.

Next Steps

• State Street Corporation will continue to hold its shares in Akebia Therapeutics Inc. in the ordinary course of business.
• Further filings may be required if State Street Corporation's beneficial ownership percentage changes significantly.

Key Dates

Keywords

Schedule 13G, State Street Corporation, Akebia Therapeutics Inc., Beneficial Ownership, Common Stock, Institutional Investor, Securities Exchange Act of 1934